Global Diagnostic Radiopharmaceuticals and Contrast Media Market: Key Developments
In October 2022, Duchem Bio launched FACBC, the world’s first radiopharmaceutical used when diagnosing prostate cancer patients, in Korea. FACBC had already received approval in the U.S. and EU in 2016 and 2017, respectively, and has been applied to about 196,000 patients.
In January 2021, QSAM Biosciences Inc. announced favorable results from a study to evaluate the radioactive impurity levels in its flagship drug candidate Samarium-153-DOTMP (aka CycloSam). The results of this study are positive indicators about the safety profile and potential expanded uses of CycloSam if ultimately approved for commercial usage.
In May 2020, the U.S. Food and Drug Administration (FDA) approved the radiopharmaceutical, flortaucipir F18 of Avid Radiopharmaceuticals, which is indicated to help image a distinctive characteristic of Alzheimer’s disease.
Global Diagnostic Radiopharmaceuticals and Contrast Media Market: Key Companies Insights
The global diagnostic radiopharmaceuticals and contrast media market is highly competitive. This is attributed to the rise demand for long-term pain management from geriatric population, as a result, players in the market are focusing on launching novel products in the market.
Some of the key players in the global diagnostic radiopharmaceuticals and contrast media market are Siemens Healthineers, Nordion Inc., Lantheus Holdings Inc., Guerbet Group, GE Healthcare, Curium, Bracco Imaging SpA, Bayer AG, Cardinal Health Inc., and NTP Radioisotopes SOC Ltd.
Diagnostic Radiopharmaceuticals And Contrast Media Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients